Accordion Title #2
Despite advancements in autism research, translating these discoveries into improved care and better outcomes for those with autism, profound autism, and related neurodevelopmental disorders (NDDs) remains a challenge.
Aligning Research to Impact Autism (ARIA) is opening a Request for Applications (RFA) for institution-based, collaborative, multidisciplinary clinical research teams to join the Innovative Medicine and Precision Approaches to Clinical Trials (IMPACT) Network, a robust and collaborative international network of sites with the goal to accelerate clinical trial readiness and implementation for both syndromic and non-syndromic forms of autism.
Despite advancements in autism research, translating these discoveries into improved care and better outcomes for those with autism, profound autism, and related neurodevelopmental disorders (NDDs) remains a challenge.
Despite advancements in autism research, translating these discoveries into improved care and better outcomes for those with autism, profound autism, and related neurodevelopmental disorders (NDDs) remains a challenge.
Despite advancements in autism research, translating these discoveries into improved care and better outcomes for those with autism, profound autism, and related neurodevelopmental disorders (NDDs) remains a challenge.
Frequently Asked Questions
This RFA is open to clinical research teams in the U.S., Canada, and UK-based public or private-sector organizations, including nonprofit and for-profit institutions, that provide clinical care for individuals affected by autism spectrum disorder and related neurodevelopmental disorders. Applications must be submitted by multidisciplinary clinical research teams. The IMPACT Network will include multiple participating sites; the number is flexible and is dependent on the applications received throughout the RFA period
The pre-application consists of short answer questions and prompts designed to assess the capabilities of applying teams and their institutional capabilities and support. These questions are focused on the following areas: organizational profile, leadership profile, clinical care, clinical trials, and clinical biomarkers.
Applicants invited to submit a full application can request up to $9 million USD, which will be split across two phases: an operational ramp-up phase and a trial readiness phase.
We will select sites by December 2025 and begin work in 2026.
For inquiries about scientific priorities, eligibility requirements, and application submission, please contact grants@aligningscience.com
"*" indicates required fields
Despite advancements in autism research, translating these discoveries into improved care and better outcomes for those with autism, profound autism, and related neurodevelopmental disorders (NDDs) remains a challenge.
Despite advancements in autism research, translating these discoveries into improved care and better outcomes for those with autism, profound autism, and related neurodevelopmental disorders (NDDs) remains a challenge.
Despite advancements in autism research, translating these discoveries into improved care and better outcomes for those with autism, profound autism, and related neurodevelopmental disorders (NDDs) remains a challenge.
Despite advancements in autism research, translating these discoveries into improved care and better outcomes for those with autism, profound autism, and related neurodevelopmental disorders (NDDs) remains a challenge.
Despite advancements in autism research, translating these discoveries into improved care and better outcomes for those with autism, profound autism, and related neurodevelopmental disorders (NDDs) remains a challenge.
Despite advancements in autism research, translating these discoveries into improved care and better outcomes for those with autism, profound autism, and related neurodevelopmental disorders (NDDs) remains a challenge.
The ARIA IMPACT Network will be a pediatric clinical trials network focused within autism. Its goals are to:
The IMPACT Network will comprise a multisite clinical trial infrastructure enabling rapid and effective therapeutic development. This network will serve as a foundation and catalyst for all types of therapeutics – from n-of-1 studies in syndromic autism, to large-scale pharmacological trials in non-syndromic autism, to early behavioral intervention trials.
The Request for Application (RFA) process has four steps
Proposals will be accepted from any United States (including Territories of the United States), United Kingdom, and Canada-based public or private-sector organizations, including nonprofit and for-profit organizations, that provide clinical care for individuals affected by autism and related NDDs.
Applicants invited to submit a full application may request up to $9 million USD, which will be split across two phases: an operational ramp-up phase and a trial readiness phase.
The number of funded participating sites is flexible and is dependent on the applications received throughout the RFA period.
For a full list of all instructions and requirements, and to apply, download the RFA Overview. The application submission portal will open in June.
[Copy Here]